Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67


Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.

Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA.

Endocr Pathol. 2018 Dec 18. doi: 10.1007/s12022-018-9561-4. [Epub ahead of print]


Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Janovitz T, Barletta JA.

Endocr Pathol. 2018 Dec;29(4):357-364. doi: 10.1007/s12022-018-9548-1. Review.


Applications of Immunohistochemistry to Endocrine Pathology.

Higgins SE, Barletta JA.

Adv Anat Pathol. 2018 Nov;25(6):413-429. doi: 10.1097/PAP.0000000000000209.


Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients ≥70 Years Old.

Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD Jr, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE.

Thyroid. 2018 Apr;28(4):465-471. doi: 10.1089/thy.2017.0655. Epub 2018 Apr 2.


EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease.

Vaidya A, Flores SK, Cheng ZM, Nicolas M, Deng Y, Opotowsky AR, Lourenço DM Jr, Barletta JA, Rana HQ, Pereira MA, Toledo RA, Dahia PLM.

N Engl J Med. 2018 Mar 29;378(13):1259-1261. doi: 10.1056/NEJMc1716652. No abstract available.


Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule.

Angell TE, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD Jr, Nehs MA.

Ann Surg Oncol. 2018 May;25(5):1410-1417. doi: 10.1245/s10434-018-6421-x. Epub 2018 Mar 8.


Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).

Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA.

Endocr Pathol. 2018 Mar;29(1):68-74. doi: 10.1007/s12022-018-9515-x.


Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.


A user's guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Hung YP, Barletta JA.

Histopathology. 2018 Jan;72(1):53-69. doi: 10.1111/his.13363. Review.


Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?

Xu B, Farhat N, Barletta JA, Hung YP, Biase D, Casadei GP, Onenerk AM, Tuttle RM, Roman BR, Katabi N, Nosé V, Sadow P, Tallini G, Faquin WC, Ghossein R.

Endocrine. 2018 Jan;59(1):143-150. doi: 10.1007/s12020-017-1484-1. Epub 2017 Dec 4.


Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists.

Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, LiVolsi VA, Nikiforov YE, Tallini G, Thompson LD.

Mod Pathol. 2018 Jan;31(1):39-55. doi: 10.1038/modpathol.2017.130. Epub 2017 Oct 20. Review.


Differential Growth Rates of Benign vs. Malignant Thyroid Nodules.

Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD Jr, Nehs MA, Zavacki AM, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4642-4647. doi: 10.1210/jc.2017-01832.


Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH.

Int J Oral Maxillofac Surg. 2018 May;47(5):568-577. doi: 10.1016/j.ijom.2017.09.006. Epub 2017 Sep 29.


Bilateral acute angle closure in a patient with dengue fever: a case report.

Levaggi ND, Lucas AN, Barletta JÁE.

Arq Bras Oftalmol. 2017 Jul-Aug;80(4):266-267. doi: 10.5935/0004-2749.20170065.


Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.

Strickland KC, Howitt BE, Barletta JA, Cibas ES, Krane JF.

Cancer Cytopathol. 2018 Feb;126(2):86-93. doi: 10.1002/cncy.21922. Epub 2017 Sep 15.


A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience.

Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF.

Cancer Cytopathol. 2017 Nov;125(11):854-864. doi: 10.1002/cncy.21907. Epub 2017 Sep 13.


Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.

Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, Menon M, Sun M, Barletta JA, Choueiri TK, Bellmunt J, Trinh QD, Preston MA.

Cancer. 2017 Nov 15;123(22):4346-4355. doi: 10.1002/cncr.30907. Epub 2017 Jul 25.


A case of primary secretory carcinoma of the thyroid with high-grade features.

Wu EY, Lebastchi J, Marqusee E, Lorch JH, Krane JF, Barletta JA.

Histopathology. 2017 Oct;71(4):665-669. doi: 10.1111/his.13268. Epub 2017 Jul 13. No abstract available.


Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism.

Omata K, Yamazaki Y, Nakamura Y, Anand SK, Barletta JA, Sasano H, Rainey WE, Tomlins SA, Vaidya A.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1792-1796. doi: 10.1210/jc.2016-4007.


The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.

Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA.

Endocr Pathol. 2017 Jun;28(2):171-176. doi: 10.1007/s12022-017-9476-5.


Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.

Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell TE.

Cancer Cytopathol. 2017 May;125(5):313-322. doi: 10.1002/cncy.21827. Epub 2017 Feb 2.


Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.

Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA.

Thyroid. 2017 Apr;27(4):506-511. doi: 10.1089/thy.2016.0583. Epub 2017 Feb 24.


Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer.

Sullivan MC, Graham PH, Alexander EK, Ruan DT, Nehs MA, Gawande AA, Moore FD Jr, Howitt BE, Strickland KC, Krane JF, Barletta JA, Cho NL.

J Am Coll Surg. 2017 Jun;224(6):1021-1027. doi: 10.1016/j.jamcollsurg.2016.12.007. Epub 2016 Dec 23.


Radiation-associated neoplasia: clinical, pathological and genomic correlates.

Sholl LM, Barletta JA, Hornick JL.

Histopathology. 2017 Jan;70(1):70-80. doi: 10.1111/his.13069. Review.


Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD Jr, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM.

Clin Cancer Res. 2017 May 1;23(9):2367-2373. doi: 10.1158/1078-0432.CCR-16-2154-T. Epub 2016 Oct 17.


Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK.

J Clin Endocrinol Metab. 2016 Dec;101(12):4938-4944. Epub 2016 Sep 30.


Coming to terms with NIFTP: A provisional approach for cytologists.

Krane JF, Alexander EK, Cibas ES, Barletta JA.

Cancer Cytopathol. 2016 Nov;124(11):767-772. doi: 10.1002/cncy.21769. Epub 2016 Aug 26. Review. No abstract available.


Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis.

Strickland KC, Vivero M, Jo VY, Lowe AC, Hollowell M, Qian X, Wieczorek TJ, French CA, Teot LA, Sadow PM, Alexander EK, Cibas ES, Barletta JA, Krane JF.

Thyroid. 2016 Oct;26(10):1466-1471. Epub 2016 Sep 8.


Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.

Wong KS, Angell TE, Strickland KC, Alexander EK, Cibas ES, Krane JF, Barletta JA.

Thyroid. 2016 Jul;26(7):911-5. doi: 10.1089/thy.2015.0644.


Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA.

JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.


Adrenal Tumors in Adults.

Pinto A, Barletta JA.

Surg Pathol Clin. 2015 Dec;8(4):725-49. doi: 10.1016/j.path.2015.07.005. Review.


Fine-needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcinoma.

Howitt BE, Chang S, Eszlinger M, Paschke R, Drage MG, Krane JF, Barletta JA.

Am J Clin Pathol. 2015 Dec;144(6):850-7. doi: 10.1309/AJCPEIE12POICULI.


The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk.

Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2015 Dec;100(12):4434-40. doi: 10.1210/jc.2015-3100. Epub 2015 Oct 14.


Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.

Mirkovic J, Sholl LM, Garcia E, Lindeman N, MacConaill L, Hirsch M, Dal Cin P, Gorman M, Barletta JA, Nucci MR, McCluggage WG, Howitt BE.

Mod Pathol. 2015 Nov;28(11):1504-14. doi: 10.1038/modpathol.2015.103. Epub 2015 Sep 4.


The variable phenotype and low-risk nature of RAS-positive thyroid nodules.

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD Jr, Alexander EK.

BMC Med. 2015 Aug 7;13:184. doi: 10.1186/s12916-015-0419-z.


GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.

Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, McCluggage WG, Oliva E, Hirsch MS.

Am J Surg Pathol. 2015 Oct;39(10):1411-9. doi: 10.1097/PAS.0000000000000471.


The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories.

Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA.

Thyroid. 2015 Sep;25(9):987-92. doi: 10.1089/thy.2014.0612. Epub 2015 Jul 29.


GATA3 expression in gestational trophoblastic tissues and tumours.

Mirkovic J, Elias K, Drapkin R, Barletta JA, Quade B, Hirsch MS.

Histopathology. 2015 Nov;67(5):636-44. doi: 10.1111/his.12681. Epub 2015 May 12.


BRAF V600E mutation-specific antibody: A review.

Ritterhouse LL, Barletta JA.

Semin Diagn Pathol. 2015 Sep;32(5):400-8. doi: 10.1053/j.semdp.2015.02.010. Epub 2015 Feb 7. Review.


Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma.

Howitt BE, Paulson VA, Barletta JA.

Histopathology. 2015 Oct;67(4):579-82. doi: 10.1111/his.12680. Epub 2015 Apr 9. No abstract available.


HER2 as a target in invasive urothelial carcinoma.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J.

Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.


Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.

Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, Mullane SA, Leow JJ, Barletta JA, Bellmunt J, Morote J.

Br J Cancer. 2015 Feb 3;112(3):468-74. doi: 10.1038/bjc.2014.633. Epub 2014 Dec 23.


Poorly Differentiated Thyroid Carcinoma.

Setia N, Barletta JA.

Surg Pathol Clin. 2014 Dec;7(4):475-89. doi: 10.1016/j.path.2014.08.001. Epub 2014 Sep 30. Review.


Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH.

N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.


Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma.

Pinto A, Signoretti S, Hirsch MS, Barletta JA.

Histopathology. 2015 May;66(6):901-4. doi: 10.1111/his.12509. Epub 2015 Jan 23. No abstract available.


Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 Oct;4(10):1140-53. doi: 10.1158/2159-8290.CD-14-0623. Epub 2014 Aug 5.


FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE.

Cancer Med. 2014 Aug;3(4):835-44. doi: 10.1002/cam4.262. Epub 2014 May 21.


Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.

Clin Cancer Res. 2014 Apr 1;20(7):1873-83. doi: 10.1158/1078-0432.CCR-13-0759. Epub 2014 Jan 31.


Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Chirieac LR, Barletta JA, Yeap BY, Richards WG, Tilleman T, Bueno R, Baldini EH, Godleski J, Sugarbaker DJ.

J Clin Oncol. 2013 Dec 20;31(36):4544-9. doi: 10.1200/JCO.2013.49.9616. Epub 2013 Nov 18.


Identification of succinate dehydrogenase-deficient bladder paragangliomas.

Mason EF, Sadow PM, Wagner AJ, Remillard SP, Flood TA, Belanger EC, Hornick JL, Barletta JA.

Am J Surg Pathol. 2013 Oct;37(10):1612-8. doi: 10.1097/PAS.0b013e318293d83c.


Supplemental Content

Loading ...
Support Center